What did the study show?

Results reveal the proven benefits of early treatment of MMVD—before the onset of CHF1

15-month delay

in time to composite primary endpoint compared with dogs receiving placebo*

60%more time

in asymptomatic stage B2
of heart disease*

10% more life

without CHF signs that impact quality of life or
cardiac-related death

Dogs who received pimobendan experienced a 15-month delay in onset of clinical signs of CHF, cardiac-related death, or euthanasia
versus dogs in the placebo group.

Median time to onset of CHF or cardiac-related death (days)
Median time to onset of CHF or cardiac-related death (days)

At 1228 days, there were more than twice as many dogs in the pimobendan group that were still alive and had not reached the primary endpoint versus the placebo group.*

Pimobendan group vs Placebo group at 1228 days
Included total dogs: pimobendan: N=179; placebo: N=180

epic study ended early due to strong results

  • The first study to be stopped due to evidence of overwhelming efficacy.
  • Early results were so positive for dogs in the pimobendan group that lead investigators decided to terminate the study following
    a recommendation from an Interim Analysis Committee.
  • Dogs in the placebo group were then given the opportunity to receive the benefits of pimobendan.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use.

Cookie Information
welcome to EPICtrial.com
Disclaimer

Are you a resident of the United States of America?

INFORMATION DISCUSSED ON EPICTRIAL.COM RELATES TO AN INDICATION THAT IS NOT REGISTERED IN THE USA.

You will now be redirected to a USA-specific website.